{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T18:11:12Z","timestamp":1793643072244,"version":"4.5.1"},"reference-count":26,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,2]],"date-time":"2023-05-02T00:00:00Z","timestamp":1682985600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.esmoop.2023.101574","type":"journal-article","created":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T07:45:46Z","timestamp":1685000746000},"page":"101574","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Efficacy of immunotherapy in mismatch repair-deficient advanced colorectal cancer in routine clinical practice. An AGEO study"],"prefix":"10.1016","volume":"8","author":[{"given":"E.","family":"Alouani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Mercier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Flecchia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Auclin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Hollebecque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Mazard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Turpin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Pernot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Dutherage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Sclafani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Ben-Abdelghani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Herve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Aparicio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"De La Fouchardi\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Perkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Hautefeuille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Jaffrelot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Gallois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Bongard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Tougeron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Ta\u00efeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Guimbaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.esmoop.2023.101574_bib1","doi-asserted-by":"crossref","first-page":"5322","DOI":"10.1158\/1078-0432.CCR-14-0332","article-title":"Mis-match repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies","volume":"20","author":"Venderbosch","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.esmoop.2023.101574_bib2","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/ijc.32879","article-title":"Prognosis and chemosensitivity of deficient MMR phenotype in patients with metastatic colorectal cancer: an AGEO retrospective multicenter study","volume":"147","author":"Tougeron","year":"2020","journal-title":"Int J Cancer"},{"issue":"23","key":"10.1016\/j.esmoop.2023.101574_bib3","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","article-title":"Pembrolizumab in microsatellite-instability\u2013high advanced colorectal cancer","volume":"383","author":"Andr\u00e9","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"26","key":"10.1016\/j.esmoop.2023.101574_bib4","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"6349","key":"10.1016\/j.esmoop.2023.101574_bib5","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"issue":"9","key":"10.1016\/j.esmoop.2023.101574_bib6","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/S1470-2045(17)30422-9","article-title":"Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study","volume":"18","author":"Overman","year":"2017","journal-title":"Lancet Oncol"},{"issue":"suppl 3","key":"10.1016\/j.esmoop.2023.101574_bib7","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1200\/JCO.2021.39.3_suppl.6","article-title":"KEYNOTE-177: phase III randomized study of pembrolizumab versus chemotherapy for microsatellite instability-high advanced colorectal cancer: 2021 Gastrointestinal Cancers Symposium","volume":"39","author":"Shiu","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2023.101574_bib8","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1200\/JCO.19.02107","article-title":"Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instability-high\/mismatch repair-deficient metastatic colorectal cancer: KEYNOTE-164","volume":"38","author":"Le","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.esmoop.2023.101574_bib9","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1093\/annonc\/mdz116","article-title":"ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1\/PD-L1 expression and tumour mutational burden: a systematic review-based approach","volume":"30","author":"Luchini","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2023.101574_bib10","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.ejca.2017.09.022","article-title":"Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability\/DNA mismatch repair deficiency","volume":"86","author":"Cohen","year":"2017","journal-title":"Eur J Cancer"},{"issue":"suppl 16","key":"10.1016\/j.esmoop.2023.101574_bib11","doi-asserted-by":"crossref","first-page":"3524","DOI":"10.1200\/JCO.2022.40.16_suppl.3524","article-title":"Prognostic role of systemic inflammatory markers in patients with metastatic MSI-h\/dMMR colorectal cancer receiving immunotherapy","volume":"40","author":"Bhamidipati","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2023.101574_bib12","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1001\/jamaoncol.2018.4942","article-title":"Association of primary resistance to immune checkpoint inhibitors in metastatic colorectal cancer with misdiagnosis of microsatellite instability or mismatch repair deficiency status","volume":"5","author":"Cohen","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.esmoop.2023.101574_bib13","doi-asserted-by":"crossref","first-page":"S1390","DOI":"10.1016\/j.annonc.2022.08.019","article-title":"LBA23 Avelumab versus standard second-line treatment chemotherapy in metastatic colorectal cancer (mCRC) patients with microsatellite instability (MSI): the SAMCO-PRODIGE 54 randomised phase II trial","volume":"33","author":"Taieb","year":"2022","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.esmoop.2023.101574_bib14","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/s41571-020-0399-6","article-title":"Immunotherapy discontinuation\u2014how, and when? Data from melanoma as a paradigm","volume":"17","author":"Robert","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.esmoop.2023.101574_bib15","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ejca.2022.05.044","article-title":"Prognostic impact of performance status on the outcomes of immune checkpoint inhibition strategies in patients with dMMR\/MSI-H metastatic colorectal cancer","volume":"172","author":"Mazzoli","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.esmoop.2023.101574_bib16","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ejca.2021.03.043","article-title":"The pan-immune-inflammation value in microsatellite instability\u2013high metastatic colorectal cancer patients treated with immune checkpoint inhibitors","volume":"150","author":"Corti","year":"2021","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.esmoop.2023.101574_bib17","article-title":"Ascites and resistance to immune checkpoint inhibition in dMMR\/MSI-H metastatic colorectal and gastric cancers","volume":"10","author":"Fuc\u00e0","year":"2022","journal-title":"J\u00a0Immunother Cancer"},{"issue":"12","key":"10.1016\/j.esmoop.2023.101574_bib18","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1200\/JCO.2008.20.2879","article-title":"Pooled safety and efficacy analysis examining the effect of performance status on outcomes in nine first-line treatment trials using individual data from patients with metastatic colorectal cancer","volume":"27","author":"Sargent","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.esmoop.2023.101574_bib19","article-title":"Nomogram to predict the outcomes of patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors","volume":"9","author":"Pietrantonio","year":"2021","journal-title":"J\u00a0Immunother Cancer"},{"issue":"1","key":"10.1016\/j.esmoop.2023.101574_bib20","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/s41591-020-1131-x","article-title":"Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination","volume":"27","author":"Yu","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.esmoop.2023.101574_bib21","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.ejca.2017.07.027","article-title":"Prospective validation of a prognostic score for patients in immunotherapy phase I trials: the Gustave Roussy Immune Score (GRIm-Score)","volume":"84","author":"Bigot","year":"2017","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.esmoop.2023.101574_bib22","article-title":"Survival in early phase immuno-oncology trials: development and validation of a prognostic index","volume":"3","author":"Day","year":"2019","journal-title":"JNCI Cancer Spectr"},{"issue":"6","key":"10.1016\/j.esmoop.2023.101574_bib23","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/bjc.2017.480","article-title":"Development of a prognostic scoring\u00a0system for patients with advanced cancer enrolled in immune checkpoint inhibitor phase 1 clinical trials","volume":"118","author":"Sen","year":"2018","journal-title":"Br J Cancer"},{"key":"10.1016\/j.esmoop.2023.101574_bib24","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ejca.2022.08.034","article-title":"High serum LDH and liver metastases are the dominant predictors of primary cancer resistance to anti-PD(L)1 immunotherapy","volume":"177","author":"Dercle","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.esmoop.2023.101574_bib25","doi-asserted-by":"crossref","first-page":"S376","DOI":"10.1016\/j.annonc.2022.04.453","article-title":"LBA O-9 Botensilimab, a novel innate\/adaptive immune activator, plus balstilimab (anti-PD-1) for metastatic heavily pretreated microsatellite stable colorectal cancer","volume":"33","author":"Bullock","year":"2022","journal-title":"Ann Oncol"},{"issue":"15","key":"10.1016\/j.esmoop.2023.101574_bib26","doi-asserted-by":"crossref","first-page":"3776","DOI":"10.3390\/cancers13153776","article-title":"Association of the lung immune prognostic index with immunotherapy outcomes in mismatch repair deficient tumors","volume":"13","author":"Auclin","year":"2021","journal-title":"Cancers"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702923008050?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702923008050?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:31:02Z","timestamp":1761856262000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702923008050"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S2059702923008050"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2023.101574","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of immunotherapy in mismatch repair-deficient advanced colorectal cancer in routine clinical practice. An AGEO study","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2023.101574","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"101574"}}